⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29951313 | 1.00 | — | — | |
| SCHEMBL303150 | 0.82 | CCR1 (0.55) | — | |
| Hydrochloric Acid SCHEMBL27613798 | 0.79 | CCR1 (0.52) | — | |
| SCHEMBL25403236 | 0.76 | — | — | |
| SCHEMBL4325487 | 0.76 | — | — | |
| SCHEMBL2151538 | 0.75 | CCR1 (0.48) | — | |
| SCHEMBL29476108 | 0.75 | CCR1 (0.48) | — | |
| SCHEMBL13474826 | 0.73 | — | — | |
| Formic Acid Methyl Ester SCHEMBL28287915 | 0.73 | GRM4 (0.31) | — | |
| SCHEMBL18259179 | 0.73 | TERT (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545683-B2 | CBP/catenin signaling pathway inhibitors and uses thereof | 3+2 PHARMA, LLC (US) | 2026-02-10 | — | — | US | disclosed |
| US-12516067-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2026-01-06 | — | — | US | disclosed |
| US-12384770-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-08-12 | — | — | US | disclosed |
| US-20250145595-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNITED STATES GOVERNMENT | 2025-05-08 | — | — | US | disclosed |
| US-20240343721-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-10-17 | — | — | US | disclosed |
| US-20240294503-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2024-09-05 | — | — | US | disclosed |
| CN-118541365-A | Antagonists of muscarinic acetylcholine receptor M4 | 范德堡大学 | 2024-08-23 | — | — | CN | disclosed |
| US-20240228468-A1 | N-(6-((OCTAHYDROCYCLOPENTA[C]PYRROL-5-YI)AMINO)PYRIDAZIN-3-YL)PHENYL)CARBOXAMIDE AND (6- ((OCTAHYDROCYCLOPENTA[C]PYRROL-5-YL)AMINO)PYRIDAZIN-3-YL)BENZAMIDE DERIVATIVES AS MACHR M4 ANTAGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | VANDERBILT UNIVERSITY | 2024-07-11 | — | — | US | disclosed |
| CN-116425717-B | C2-site indoline derivative containing quaternary carbon center as well as preparation method and application thereof | 重庆医科大学 | 2024-06-21 | — | — | CN | disclosed |
| US-20240174655-A1 | INDAZOLE DERIVATIVES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2024-05-30 | — | — | US | disclosed |
| EP-1501825-A2 | SUBSTITUTED IMIDAZOLYLMETHYL PYRIDINE AND PYRAZINE DERIVATIVES: GABA A RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004041809-A2 | SUBSTITUTED IMIDAZOLYLMETHYL PYRIDINE AND PYRAZINE DERIVATIVES AND THEIR USE AS GABAA RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2004-05-21 | — | — | WO | disclosed |
| EP-1368342-A2 | BENZIMIDAZOLE AND PYRIDYLIMIDAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | NEUROGEN CORPORATION (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20030220348-A1 | Substituted imidazolylmethyl pyridine and pyrazine deriviatives GABAa receptor ligands | NEUROGEN CORPORATION | 2003-11-27 | — | — | US | disclosed |
| EP-0946546-B1 | PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, METHOD OF PREPARING AND APPLICATION AS MEDICINE | PF MEDICAMENT (FR) | 2003-06-25 | — | — | EP | disclosed |
| US-20030069257-A1 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION | 2003-04-10 | — | — | US | disclosed |
| WO-2002050062-A2 | BENZIMIDAZOLE AND PYRIDYLIMIDAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | NEUROGEN CORPORATION (US) | 2002-06-27 | — | — | WO | disclosed |
| US-6020345-A | Pyridin-2-yl-methylamine derivatives, method of preparing and application as medicine | PIERRE FABRE MEDICAMENT (FR) | 2000-02-01 | — | — | US | disclosed |
| EP-0946546-A1 | PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, METHOD OF PREPARING AND APPLICATION AS MEDICINE | PIERRE FABRE MEDICAMENT (FR) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998022459-A1 | PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, METHOD OF PREPARING AND APPLICATION AS MEDICINE | PIERRE FABRE MEDICAMENT (FR) | 1998-05-28 | — | — | WO | disclosed |